debt_leverage_profile
1.20x Total Debt / Equity (Elevated leverage)
High
SEC-XBRL
interest_rate_sensitivity
A 20bps rate increase adds ~$2M annual interest expense given ~$200M variable-rate debt; moderate sensitivity at ~3.5x net leverage
Inferred
Agent_Inference
geopolitical_supply_exposure
High intensity; OPEC+ supply decisions and Russia-Ukraine conflict drive price volatility.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Active pharmaceutical ingredients sourced from China/India; Israeli manufacturing operations exposed to Middle East geopolitical instability
Inferred
Agent_Inference
international_expansion_readiness
Brazil BRL, Israeli ILS, and EU EUR devaluation risk; BRL historically most volatile, representing meaningful revenue exposure with limited natural hedging
Inferred
Agent_Inference
geographic_footprint
Top markets: Brazil (~15% revenue), Israel (~10%), Europe (~10%); BRL devaluation is primary risk given Brazil's history of currency volatility
Inferred
Agent_Inference
commodity_exposure_profile
High intensity; commodities: Crude Oil, Natural Gas, Coal, Refined Petroleum Products, Uranium, Steel (equipment); geopolitical: OPEC+ supply decisions and Russia-Ukraine conflict drive price volatility.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
No single vendor exceeds 30% of input costs publicly; API-sourced veterinary biologics from select suppliers create moderate non-substitutable dependency
Inferred
Agent_Inference
business_model_type_primary
Phibro is a manufacturing-centric animal health company; cloud infrastructure termination would disrupt ERP/CRM but not core production or revenue generation
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital/data operations (sales analytics, regulatory submissions) would face 30-60 day disruption; no cloud-native revenue stream at risk
Inferred
Agent_Inference
switching_cost_profile
Minimal API coupling risk; Phibro relies on internal manufacturing systems and legacy ERP; no material third-party API dependency in revenue-critical workflows
Inferred
Agent_Inference
howey_test_risk_index
Very low Howey Test risk; revenue model is product sales of veterinary pharmaceuticals and nutritional specialties — classic commercial goods transaction
Inferred
Agent_Inference
regulatory_burden_tier
High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR exposure via EU sales operations; CCPA exposure limited as B2B focus reduces consumer PII handling; no known enforcement actions
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; Phibro holds sub-10% market share in most animal health segments; competes against Zoetis, Merck Animal Health, Elanco with no dominant position
Inferred
Agent_Inference
regulatory_exposure_profile
High burden; regimes: EPA, FERC, DOE, CFTC, OSHA, SEC; Accelerating emissions mandates and methane rules threaten capex economics.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~70% transactional product sales, ~30% quasi-recurring via long-term supply agreements with integrators and large livestock producers
Inferred
Agent_Inference
monetization_vector
Primary monetization via direct product sales of vaccines, antibiotics, and feed additives; secondary via performance nutritional chemicals with volume-based pricing
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing with commodity input exposure (raw API costs); limited ability to pass through rapid input cost spikes given contract-bound large customers
Inferred
Agent_Inference
pricing_power_rating
Moderate pricing power (6/10); branded veterinary products command premium but generic competition in antibiotics limits aggressive price increases
Inferred
Agent_Inference
target_gross_margin_bracket
30.9% Gross Margin (Moderate (20-40%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; products are proprietary formulations requiring purchase; no open-source or free alternative pathway exists for core animal health therapeutics
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; manufacturing scale efficiencies allow ~15-20% revenue growth with minimal incremental headcount in production
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth driven by raw material and manufacturing capacity, not headcount; incremental EBITDA margin expansion expected at scale above $1B revenue
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Phibro operates no franchise network — direct manufacturing and distribution model with no franchisee compliance drift risk
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC efficiency improves via existing distributor relationships; key constraint is regulatory approval timelines for new geographies, not sales capacity
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; animal health product value is independent of user base size; brand reputation and regulatory approvals are moat drivers instead
Inferred
Agent_Inference
asset_efficiency_ratio
5.0% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Tier 2 recession resistant; livestock and poultry production is largely non-discretionary; companion animal segment more vulnerable to consumer spending pullback
Inferred
Agent_Inference
customer_segment_primary
Large integrated poultry and swine producers (e.g., Tyson, Smithfield affiliates); top 10 customers likely represent 30-40% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Independent livestock producers, aquaculture operators, and international distributors serving emerging market agricultural sectors
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "19-0000 Life, Physical, and Social Science Occupations", "23-0000 Legal Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "53-0000 Transportation and Material Moving Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.33 (HIL — ~33% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocation skews toward maintaining and modestly expanding existing manufacturing facilities; limited reallocation toward future-state digital or biotech infrastructure
Inferred
Agent_Inference
sec_cik
0001069899
High
SEC-EDGAR
ticker
PAHC
High
SEC-EDGAR